Are Analysts Bearish Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) After Last Week?

February 15, 2018 - By Clifton Ray

 Are Analysts Bearish Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) After Last Week?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Ratings Coverage

Among 5 analysts covering Sunesis Pharmaceuticals (NASDAQ:SNSS), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Sunesis Pharmaceuticals had 11 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has “Outperform” rating given on Friday, July 29 by Wells Fargo. As per Monday, December 11, the company rating was upgraded by Wells Fargo. The firm has “Hold” rating by Cantor Fitzgerald given on Thursday, July 27. Oppenheimer initiated the shares of SNSS in report on Monday, November 20 with “Buy” rating. The firm has “Market Perform” rating given on Friday, July 24 by Cowen & Co. The firm has “Market Perform” rating given on Tuesday, December 5 by Wells Fargo. As per Friday, July 24, the company rating was downgraded by TH Capital. The stock has “Buy” rating by Oppenheimer on Thursday, December 14. The stock has “Hold” rating by Cantor Fitzgerald on Tuesday, July 18. The rating was downgraded by Cantor Fitzgerald on Friday, July 24 to “Hold”. Below is a list of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) latest ratings and price target changes.

14/12/2017 Broker: Oppenheimer Rating: Buy New Target: $7.0 Initiate
11/12/2017 Broker: Wells Fargo Rating: Buy Upgrade
05/12/2017 Broker: Wells Fargo Old Rating: Outperform New Rating: Market Perform Downgrade
20/11/2017 Broker: Oppenheimer Rating: Buy New Target: $7.0 Initiate
02/11/2017 Broker: Cowen & Co Rating: Hold

The stock increased 0.33% or $0.02 during the last trading session, reaching $6.04. About 94,099 shares traded. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has risen 8.33% since February 15, 2017 and is uptrending. It has underperformed by 8.37% the S&P500.

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company has market cap of $206.86 million. The firm is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia . It currently has negative earnings. It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.

More notable recent Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) news were published by: Streetinsider.com which released: “Wells Fargo Upgrades Sunesis Pharmaceuticals Inc. (SNSS) to Outperform Citing …” on December 11, 2017, also Globenewswire.com with their article: “Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and …” published on July 27, 2017, Seekingalpha.com published: “Sunesis Pharmaceuticals: SNS-062 Could Be The Company’s Salvation” on August 29, 2017. More interesting news about Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) were released by: Globenewswire.com and their article: “Sunesis Pharmaceuticals Announces Withdrawal of European Marketing …” published on May 01, 2017 as well as Seekingalpha.com‘s news article titled: “Sunesis up 28% after ASH conference; Wells Fargo analyst reconsiders” with publication date: December 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.